Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032

Overview of attention for article published in Journal for Immunotherapy of Cancer, November 2015

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (75th percentile)
Good Attention Score compared to outputs of the same age and source (79th percentile)

Mentioned by

patent: 3 patents

Readers on

mendeley: 26 Mendeley

Summary Patents

So far, Altmetric has seen 3 patents that reference this research output.

USE OF ANTI-PD-1 ANTIBODY IN THE TREATMENT OF PATIENTS WITH COLORECTAL CANCER

Grant EP-3464373-B1

European Patent Office

ANTI-PD-1 ANTIBODY FOR USE IN A METHOD OF TREATMENT OF RECURRENT SMALL CELL LUNG CANCER

Application WO-2017210631-A1

World Intellectual Property Organisation (WIPO)

TREATMENT OF LUNG CANCER USING A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND AN ANTI-CTLA-4…

Application WO-2017087870-A1

World Intellectual Property Organisation (WIPO)

This page shows the most recent patents that mention this research output.

Click here to find out how to access more activity.